Sun Pharma

Sun Pharma to Acquire Checkpoint Therapeutics

Indian generic drug maker Sun Pharma agreed to acquire US immunotherapy and targeted oncology company Checkpoint Therapeutics for an upfront value of $355 million. The transaction is expected to be completed in the second quarter of 2025 and is subject to customary closing conditions.

News

India's Sun Pharma, US Merck in Generics Joint Venture

Top-Feature

Hamilton Bonaduz AG

Optimize Your Process with Smart Oxygen Sensors for Inertization and Blanketing Applications

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

CHEManager International c/o Wiley-VCH GmbH

20 Years of CHEManager International

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

CHEManager International c/o Wiley-VCH GmbH

API Manufacturing

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.